ACHV Losses Widen, Raises $10M in Public Offering

TL;DR

**ACHV is burning cash and diluting shareholders to stay afloat; avoid until they show a clear path to profitability.**

AI Summary

ACHIEVE LIFE SCIENCES, INC. reported a net loss of $10.2 million for the three months ended June 30, 2025, compared to a net loss of $9.5 million for the same period in 2024, representing a 7.4% increase in loss. For the six months ended June 30, 2025, the net loss was $20.5 million, up from $18.7 million in 2024, an increase of 9.6%. Research and development expenses decreased to $6.8 million for the three months ended June 30, 2025, from $7.1 million in 2024, a 4.2% reduction. General and administrative expenses, however, increased to $3.4 million for the three months ended June 30, 2025, from $2.4 million in 2024, a 41.7% rise. The company completed a public offering in June 2025, issuing 1,725,000 shares of common stock and warrants, generating gross proceeds of approximately $10.0 million. This offering, along with a February 2024 registered direct offering that raised $10.0 million, significantly impacted their cash position. The company's strategic outlook remains focused on advancing its clinical programs, particularly with cytisinicline, while managing its cash burn. Risks include continued reliance on external financing and the inherent uncertainties of drug development.

Why It Matters

ACHV's continued net losses and reliance on dilutive public offerings signal a challenging path for investors, as shareholder value could be further eroded. The increased general and administrative expenses, despite a slight reduction in R&D, raise questions about operational efficiency and resource allocation in a competitive biotech landscape. For employees, the financial strain could lead to job insecurity or slower growth opportunities. Customers, primarily future patients, depend on the company's ability to secure funding to bring its drug candidates, like cytisinicline, to market, making these financial moves critical for product development. The broader market will watch if ACHV can effectively leverage its new capital to achieve clinical milestones and attract more stable funding.

Risk Assessment

Risk Level: high — The company reported a net loss of $10.2 million for the three months ended June 30, 2025, and a $20.5 million net loss for the six months ended June 30, 2025, indicating significant ongoing cash burn. Their reliance on public offerings, such as the June 2025 offering that raised $10.0 million, demonstrates a need for external financing, which can lead to substantial shareholder dilution.

Analyst Insight

Investors should exercise extreme caution and consider holding off on investing in ACHV until the company demonstrates a clear path to profitability or secures non-dilutive funding. Monitor future filings for significant clinical trial advancements or strategic partnerships that could reduce their reliance on equity financing.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10.2M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $10.2M — Net Loss (Q2 2025) (Increased from $9.5M in Q2 2024, a 7.4% rise.)
• $20.5M — Net Loss (H1 2025) (Increased from $18.7M in H1 2024, a 9.6% rise.)
• $6.8M — R&D Expenses (Q2 2025) (Decreased by 4.2% from $7.1M in Q2 2024.)
• $3.4M — G&A Expenses (Q2 2025) (Increased by 41.7% from $2.4M in Q2 2024.)
• $10.0M — Gross Proceeds from June 2025 Public Offering (New capital raised through issuance of common stock and warrants.)
• 1,725,000 — Shares Issued in June 2025 Public Offering (Represents significant shareholder dilution.)

Key Players & Entities

• ACHIEVE LIFE SCIENCES, INC. (company) — filer of the 10-Q
• $10.2 million (dollar_amount) — net loss for Q2 2025
• $9.5 million (dollar_amount) — net loss for Q2 2024
• $20.5 million (dollar_amount) — net loss for H1 2025
• $18.7 million (dollar_amount) — net loss for H1 2024
• $6.8 million (dollar_amount) — R&D expenses for Q2 2025
• $7.1 million (dollar_amount) — R&D expenses for Q2 2024
• $3.4 million (dollar_amount) — G&A expenses for Q2 2025
• $2.4 million (dollar_amount) — G&A expenses for Q2 2024
• cytisinicline (other) — key drug candidate

FAQ

Risk Factors

• Reliance on External Financing [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional funding. The June 2025 public offering raised $10.0 million, but the net loss of $10.2 million in Q2 2025 and $20.5 million in H1 2025 indicates a significant cash burn rate. Future funding needs remain a critical risk.
• Drug Development Uncertainties [high — operational]: Achieve Life Sciences is focused on advancing its clinical programs, particularly with cytisinicline. The inherent risks and uncertainties of drug development, including clinical trial outcomes, regulatory approvals, and market acceptance, pose a significant risk to the company's future success.
• Increased General and Administrative Expenses [medium — financial]: G&A expenses rose by 41.7% to $3.4 million in Q2 2025 from $2.4 million in Q2 2024. While R&D expenses decreased slightly, this significant increase in G&A warrants close monitoring as it contributes to the widening net loss.
• Shareholder Dilution [medium — financial]: The June 2025 public offering issued 1,725,000 shares of common stock. While this provided capital, it also resulted in significant dilution for existing shareholders, impacting the value of their holdings.

Industry Context

Achieve Life Sciences operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on novel therapeutics. The industry is characterized by long development cycles, significant regulatory hurdles, and a high rate of failure. Companies like Achieve rely heavily on external funding to advance their pipelines, making access to capital a critical success factor.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Achieve Life Sciences is subject to stringent regulatory oversight from bodies like the FDA. Successful navigation of clinical trials and obtaining regulatory approval for cytisinicline are paramount. Any delays or adverse findings in the regulatory process could severely impact the company's prospects.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Track progress of cytisinicline clinical trials and regulatory milestones.
3. Analyze the sustainability of increased G&A expenses.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported a net loss of $10.2 million, with G&A expenses increasing significantly.
• 2025-06-26: Public Offering Completed — Raised approximately $10.0 million in gross proceeds through the issuance of 1,725,000 shares and warrants, impacting cash position and causing dilution.
• 2024-07-25: Convertible Term Loan Agreement — Entered into a convertible term loan agreement, indicating a need for financing and potential future dilution.
• 2024-01-01: Start of H1 2024 — The first half of 2024 saw a net loss of $18.7 million.
• 2024-02-01: Registered Direct Offering — Raised $10.0 million, providing capital but also potentially impacting cash flow and shareholder value.

Glossary

Cytisinicline

A plant-derived compound being developed by Achieve Life Sciences for smoking cessation. (It is the company's lead clinical candidate, and its advancement is central to the company's strategy and future revenue potential.)

Public Offering

A sale of securities to the public, typically to raise capital. (The company recently completed a public offering in June 2025, raising $10.0 million, which is crucial for funding its operations and clinical development.)

Registered Direct Offering

A type of offering where a company sells newly issued shares directly to a select group of investors, often at a discount. (Achieve Life Sciences conducted such an offering in February 2024, raising $10.0 million, highlighting its reliance on equity financing.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (The company reported a net loss of $10.2 million for Q2 2025, indicating ongoing operational costs exceeding revenue generation.)

General and Administrative Expenses (G&A)

Costs incurred for the overall management and administration of a business, not directly tied to production or sales. (A significant increase in G&A expenses (41.7%) in Q2 2025 is a key factor contributing to the widening net loss.)

Research and Development Expenses (R&D)

Costs incurred in the process of discovering, designing, and improving products or processes. (While R&D expenses decreased slightly in Q2 2025, they remain a substantial cost for a life sciences company focused on clinical development.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Achieve Life Sciences, Inc. has seen an increase in its net loss, with Q2 2025 losses rising by 7.4% to $10.2 million. While R&D expenses saw a slight reduction, General and Administrative expenses surged by 41.7%, contributing to the wider loss. The company has actively raised capital through offerings in both periods, with a $10.0 million public offering in June 2025 following a similar amount raised in February 2024, indicating a continued need for external funding.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ACHV The Nasdaq Capital M

Filing Documents

• achv-20250630.htm (10-Q) — 2192KB
• achv-ex10_1.htm (EX-10.1) — 238KB
• achv-ex31_1.htm (EX-31.1) — 12KB
• achv-ex31_2.htm (EX-31.2) — 12KB
• achv-ex32_1.htm (EX-32.1) — 7KB
• achv-ex32_2.htm (EX-32.2) — 7KB
• 0000950170-25-104571.txt ( ) — 9038KB
• achv-20250630.xsd (EX-101.SCH) — 1385KB
• achv-20250630_htm.xml (XML) — 1432KB

Financial Information

Part I. Financial Information 5 Item 1 Consolidated Financial Statements (unaudited) 5 Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 5 Consolidated Statements of Loss and Comprehensive Loss (unaudited) for the three and six months ended June 30, 2025 and June 30, 2024 6 Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2025 and June 30, 2024 7 Consolidated Statements of Stockholders' Equity (unaudited) for the six months ended June 30, 2025 and June 30, 2024 8

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 4.

Controls and Procedures

Controls and Procedures 30

Other Information

Part II. Other Information 31 Item 1A.

Risk Factors

Risk Factors 31 Item 6. Exhibits 64 Items 2, 3, 4 and 5 are not applicable and therefore have been omitted.

Signatures

Signatures 65 2 INFORMATION REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are not historical facts. You can find many of these statements by looking for words like "believes," "expects," "anticipates," "estimates," "may," "should," "will," "could," "plan," "intend" or similar expressions in this Quarterly Report on Form 10-Q or in documents incorporated by reference into this Quarterly Report on Form 10-Q. We intend that such forward-looking statements be subject to the safe harbors created thereby. Examples of these forward-looking statements include, but are not limited to: anticipated regulatory filings and U.S. Food and Drug Administration, or FDA, responses, recommendations, requirements or additional future clinical trials; our ability to raise additional capital as needed to fund our planned development and commercialization efforts and service our existing debt; the potential benefits and differentiated profile, FDA approval, commercialization and commercial market for cytisinicline; the performance of, and our ability to obtain sufficient supply of cytisinicline in a timely manner from, third-party suppliers and man

View Full Filing

View this 10-Q filing on SEC EDGAR